Abaloparatide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Available by prescription under the brand name Tymlos for treatment of osteoporosis in postmenopausal women and men at high fracture risk. Not subject to the FDA Compounding Category 2 (FDA-19) list; fda19 flag is false.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Abaloparatide

Origin

Synthetic 34-amino acid peptide derived from parathyroid hormone-related protein (PTHrP 1-34), engineered to preferentially engage the RG conformation of the PTH type-1 receptor (PTH1R) over teriparatide.

Registry IDs

PubChem CID

76943386

CAS

247062-33-5

InChIKey

BVISQZFBLRSESR-XSCWXTNMSA-N

Molecular formula

C174H300N56O49

Molar mass

3961 g/mol

Monoisotopic

3958.2704702 Da

InChIKey

BVISQZFBLRSESR-XSCWXTNMSA-N

Appearance

Clear, colorless solution for injection (pre-filled pen, commercial form)

Solubility

Soluble in aqueous solution at physiological pH; peptide is provided as solution…

Sequence not available in current seed.

Stability: Peptide is stable as supplied solution; avoid freezing and direct light exposure. Stability of research-grade material depends on vendor specifications.

Vial sizes

null mg

Purity grades

pharmaceutical grade (commercial)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Abaloparatide acts as a selective agonist at PTH1R, binding with greater affinity to the G-protein-coupled RG conformation and lower affinity to the G-protein-independent R0 conformation compared with PTH(1-34)
• This conformational bias produces more transient cAMP responses in PTH1R-expressing cells, shifting the balance of bone remodeling toward osteoblast-mediated bone formation with comparatively less stimulation of osteoclastic bone resorption
• The result is net anabolic activity at trabecular, endocortical, and periosteal surfaces, driving increases in bone mineral density at the lumbar spine and hip

Pharmacokinetics (ADME)

Half-life

approximately 1 hour (subcutaneous)

Clearance

Non-specific proteolytic degradation; fragments eliminated by renal clearance

PK–PD note: Absolute bioavailability ~36% after 80 mcg SC dose in healthy women; plasma protein binding ~70%; volume of distribution ~50 L. Cmax and AUC increase proportionally in renal impairment (AUC up to 2.1-…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Bonifacio M et al. The Efficacy and Safety of Abaloparatide in Osteoporosis: A Systematic Review and Meta-Analysis. J Clin Med. 2026;15(2):673. — PRISMA 2020 systematic review/meta-analysis; PubMed PMID 41598611
• Efficacy and safety of abaloparatide, denosumab, teriparatide, bisphosphonates in male osteoporosis: systematic review and Bayesian network meta-analysis.
• Miller PD et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures (ACTIVE). JAMA. 2016;316(7):722-33. — Anchoring pivotal Phase 3 RCT (not a review, but primary evidence anchor)
• Abaloparatide - StatPearls (NCBI Bookshelf) — Mechanism overview reference
• Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations (Endocrinology). — Primary mechanistic study on RG-conformation selectivity

5 registered trials — 0 currently recruiting.

Phase 4
NCT04467983
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

ACTIVE_NOT_RECRUITING

Phase 3
NCT03710889
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

COMPLETED

Phase 1
NCT06753864
A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

NOT_YET_RECRUITING

Phase 2
NCT01674621
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

COMPLETED

Phase 1
NCT04936984
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

COMPLETED

Summary (literature)

Per the FDA-approved label (Tymlos, updated 2023), the most common adverse reactions in postmenopausal women include hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), and palpitations (5%); in men, injection site erythema (13%), dizziness (9%), arthralgia (7%), a…

WADA status

PTH analogs as a class are covered under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); abaloparatide is not explicitly named on t…

Dominant research route: SC

Phase 3 ACTIVE trial in postmenopausal women with osteoporosis (SC 80 mcg once daily); PK characterized in healthy postmenopausal women

Bioavailability: Absolute bioavailability 36% after SC 80 mcg; median Tmax 0.51 h (range 0.25–0.52 h); plasma protein binding ~70%; mean elimination half-life ~1.7 h

Approved commercial route (TYMLOS). Administered into periumbilical region of abdomen; label states do not administer IV or IM.

Phase 2/3 randomized study of abaloparatide-solid microstructured transdermal system (abaloparatide-sMTS) vs SC in postmenopausal women with osteoporosis (NCT04064411)

Bioavailability: Once-daily abaloparatide-sMTS (microneedle array coated with abaloparatide + ZnCl2) produced a consistent PK profile and s-PINP increases similar to SC in a phase 1b study; not an approved product

Investigational route developed to avoid daily SC injection; microneedle-coated patch with spring-actuated applicator. Not marketed.

Not studied as a therapeutic route; contraindicated per US label

Bioavailability: No IV/IM bioavailability established; label instructs 'Do not administer IV or IM'

Listed only as a contraindicated route in the professional monograph; included for completeness, not a studied administration pathway.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

p25 $298.00 · median $298.00 · p75 $298.00 · 6 researched vendors

Legit, COA-backed band: $250.00–$600.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$2980

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Research-grade abaloparatide (RUO) reported at 98.04% purity by HPLC (Selleck Chem, batch P109201). No independent third-party lab purity range retrieved for grey-market abaloparatide.

Independent labs cited for this compound

No FDA-classified recalls (Class I/II/III) were found for Tymlos (abaloparatide) in the FDA Enforcement Report or openFDA drug enforcement API. One MAUDE product-quality complaint (black particulate in prefilled pen, 2021) was identified but did not result in a recall classification.

Buyer red-flag checklist

• Abaloparatide is a 34-amino-acid peptide sold by numerous 'research use only' vendors; FDA approval (NDA 208743) covers only Tymlos, so non-Tymlos abaloparatide is an unapproved new drug if marketed for human use.
• Boxed warning for osteosarcoma risk (rat data) was in place 2017–2021; removed Dec 2021 but osteosarcoma precaution remains in labeling.
• MAUDE product-quality complaint (2021) reported black particulate ('black thread') in Tymlos prefilled pen.
• Independent third-party purity/dosing data for grey-market abaloparatide is sparse; Janoshik test record exists but was not retrievable.
• Enhanced pharmacovigilance for osteosarcoma required for 15 years post-approval per FDA approval package.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab test aggregate (Janoshik/MZ Biolabs/Finnrick) for abaloparatide underdosing prevalence was retrievable. A Janoshik test record exists (test 70600) but the page returned HTTP 403 and no purity/dose value could be extracted.

• Import Alert 66-41 'Detention Without Physical Examination of Unapproved New Drugs' applies generally to unapproved new drug products. Abaloparatide is an FDA-approved new drug (NDA 208743); unapproved/non-FDA-reviewed abaloparatide imports (e.g., 'research peptide' shipments marketed with disease-treatment claims) would fall under this DWPE alert. Not abaloparatide-specific on the Red List.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically listed on the WADA Prohibited List. Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog; PTH/PTHrP analogs are not enumerated under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes should verify status with their anti-doping organization via GlobalDRO.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-selection toward strong experiences (positive or negative)
• prescription-only drug limits grey-market / counterfeit discourse
• small subreddit sample (r/osteoporosis) not representative of all patients
• patient-review platforms skew toward side-effect reporting

Manually researched from reddit— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

FDA-approved synthetic PTHrP analog (Tymlos) that selectively stimulates bone formation for osteoporosis at high fracture risk. Approximately 386 articles are indexed (literature last scanned 2026-05-29). US regulatory status: FDA-approved prescription drug (Rx only). Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet